https://www.biopharmawatch.com/news/PCVX/aktuelle-trends-verbesserte-soundsysteme-win-beatz BiopharmaWatch en 2026-08-01T10:13:53.000Z Aktuelle_Trends_und_verbesserte_Soundsysteme_rund_um_win_beatz_für_Audioliebhab https://www.biopharmawatch.com/news/PCVX/destinasi-impianmu-terwujud-aviamaster1-solusi-perjalanan BiopharmaWatch en 2026-08-01T10:12:34.000Z Destinasi_impianmu_terwujud_dengan_https_aviamaster1_com_solusi_perjalanan_terba https://www.biopharmawatch.com/news/PCVX/pak-aviator-risk-reward-gameplay-strategies BiopharmaWatch en 2026-08-01T09:23:43.000Z Potential_gains_soar_with_pak_aviator_balancing_risk_and_reward_in_every_flight https://www.biopharmawatch.com/news/PCVX/affidabile-confronto-scommesse-online-nuove-strategie BiopharmaWatch en 2026-08-01T09:07:52.000Z Affidabile_confronto_per_scommesse_online_con_the-kinbet-it_it_e_nuove_strategie https://www.biopharmawatch.com/news/PCVX/genuine-excitement-awaits-chickenroad-arcade-fun BiopharmaWatch en 2026-08-01T08:48:52.000Z Genuine_excitement_awaits_with_chickenroad_for_endless_arcade_fun_and_challengin https://www.biopharmawatch.com/news/PCVX/thefunbet-insights-and-winning-approaches BiopharmaWatch en 2026-08-01T06:21:59.000Z Analysis_reveals_insights_from_https_thefunbet_co_uk_and_potential_winning_appro https://www.biopharmawatch.com/news/PCVX/adorable-adventure-chicken-road-gaming BiopharmaWatch en 2026-08-01T06:20:04.000Z Adorable_adventure_awaits_with_thechickenroad-canada_ca_and_countless_daring_das https://www.biopharmawatch.com/news/PCVX/aktuelle-trends-crown-plays1-ch-spielmechaniken BiopharmaWatch en 2026-08-01T06:15:55.000Z Aktuelle_Trends_bei_crown-plays1_ch_sowie_spannende_Spielmechaniken_entdecken https://www.biopharmawatch.com/news/CORT/hypercortisolism-resistant-hypertension-cardiovascular-disease BiopharmaWatch en 2026-08-01T01:00:13.000Z Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-q2-2026-results-clinical-trial-progress BiopharmaWatch en 2026-07-31T21:34:00.000Z FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate https://www.biopharmawatch.com/news/PFSA/profusa-signs-option-agreement-acquire-g3-vision-labs BiopharmaWatch en 2026-07-31T21:15:00.000Z Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs https://www.biopharmawatch.com/news/XRTX/xortx-announces-director-resignation BiopharmaWatch en 2026-07-31T21:00:00.000Z XORTX Announces Director Resignation https://www.biopharmawatch.com/news/ENTX/entera-bio-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-31T20:30:00.000Z Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PRPO/precipio-q2-2026-shareholder-update-call BiopharmaWatch en 2026-07-31T20:00:00.000Z Precipio Announces Q2-2026 Shareholder Update Call https://www.biopharmawatch.com/news/PCVX/aviator-game-download-risk-management BiopharmaWatch en 2026-07-31T19:37:50.000Z Potential_rewards_await_with_aviator_game_download_and_careful_risk_management_t https://www.biopharmawatch.com/news/PCVX/covid-19-coronavirus-disease-2019 BiopharmaWatch en 2026-07-31T19:25:47.000Z Coronavirus disease 2019 https://www.biopharmawatch.com/news/IMRX/aja-harbert-joins-immuneering BiopharmaWatch en 2026-07-31T16:21:41.000Z Aja Harbert https://www.biopharmawatch.com/news/PCVX/stoiximan-new-platform-launch BiopharmaWatch en 2026-07-31T15:42:40.000Z Εύκολη_πρόσβαση_στη_στοιχηματική_πλατφόρμα https://www.biopharmawatch.com/news/IMRX/paris-offor-joins-immuneering BiopharmaWatch en 2026-07-31T15:36:28.000Z Paris Offor https://www.biopharmawatch.com/news/PCVX/considerable-progress-in-competitive-gaming BiopharmaWatch en 2026-07-31T14:52:07.000Z Considerable_progress_from_initial_steps_to_advanced_play_with_https_vegasheros- https://www.biopharmawatch.com/news/PCVX/automaty-z-magnesami-niespodzianki-i-wygrane BiopharmaWatch en 2026-07-31T14:50:57.000Z Automaty_z_magnesami_czyli_niespodzianki_i_wygrane_na_https_the-magnetic-slots_n https://www.biopharmawatch.com/news/PCVX/atmosphaere-kreieren-zuhause-neu-denken-thegolisimo BiopharmaWatch en 2026-07-31T14:47:35.000Z Atmosphäre_kreieren_und_das_Zuhause_neu_denken_mit_thegolisimo_at_für_individu https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-public-offering BiopharmaWatch en 2026-07-31T14:12:00.000Z Moleculin Announces Pricing of $9.3 Million Public Offering https://www.biopharmawatch.com/news/NCEL/newcelx-announces-1-4-million-financing-premium-pricing BiopharmaWatch en 2026-07-31T13:00:00.000Z NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing https://www.biopharmawatch.com/news/SDEV/stablecoin-development-corporation-q2-2026-results BiopharmaWatch en 2026-07-31T12:30:00.000Z Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NMAD/nomad-options-trading-begins-cboe BiopharmaWatch en 2026-07-31T12:30:00.000Z NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange https://www.biopharmawatch.com/news/OGN/organon-announces-quarterly-dividend BiopharmaWatch en 2026-07-31T12:30:00.000Z Organon Announces Quarterly Dividend https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-august-2026 BiopharmaWatch en 2026-07-31T12:30:00.000Z PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 https://www.biopharmawatch.com/news/RDGT/ridgetech-fiscal-year-2026-financial-results BiopharmaWatch en 2026-07-31T12:30:00.000Z Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-quantum-platform-clinical-data-analytics BiopharmaWatch en 2026-07-31T12:20:00.000Z SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-31T12:15:00.000Z IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-positive-data-venetoclax-failure BiopharmaWatch en 2026-07-31T12:10:18.000Z Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients https://www.biopharmawatch.com/news/GCTK/lokahi-therapeutics-ai2-futures-lab-expansion BiopharmaWatch en 2026-07-31T12:00:00.000Z Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline https://www.biopharmawatch.com/news/ELUT/elutia-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-31T12:00:00.000Z Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/PMI/picard-medical-emperor-total-artificial-heart-architecture BiopharmaWatch en 2026-07-31T12:00:00.000Z Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:47:00.000Z AbbVie Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELAN/elanco-2025-impact-report-animal-health-innovation BiopharmaWatch en 2026-07-31T11:32:00.000Z Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs https://www.biopharmawatch.com/news/MDCX/medicus-pharma-uae-authorization-teverelix-endometriosis-study BiopharmaWatch en 2026-07-31T11:30:00.000Z Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis https://www.biopharmawatch.com/news/NVO/novo-nordisk-zeus-phase-3-trial-update BiopharmaWatch en 2026-07-31T11:21:00.000Z Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation https://www.biopharmawatch.com/news/INMB/inmune-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-07-31T11:15:58.805Z INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th https://www.biopharmawatch.com/news/OCGN/ocugen-participate-august-investor-conferences BiopharmaWatch en 2026-07-31T11:15:21.037Z Ocugen to Participate in Upcoming August Investor Conferences https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:13:15.202Z Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-31T11:12:24.597Z Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:01:00.000Z Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/TLSA/tiziana-reports-reduction-brain-inflammation-msatreatment BiopharmaWatch en 2026-07-31T11:00:00.000Z Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab https://www.biopharmawatch.com/news/INMB/inmune-bio-receives-rd-rebates-4-6-million BiopharmaWatch en 2026-07-31T11:00:00.000Z INmune Bio Receives R&D Rebates of Approximately $4.6 Million https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-business-update BiopharmaWatch en 2026-07-31T11:00:00.000Z Radiopharm Theranostics Reports Business Update https://www.biopharmawatch.com/news/BTSG/brightspring-health-q2-2026-financial-results BiopharmaWatch en 2026-07-31T10:00:00.000Z BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance https://www.biopharmawatch.com/news/AMGN/amgen-scholars-program-india-launch-iiit-hyderabad BiopharmaWatch en 2026-07-31T00:00:00.000Z FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD Amgen (NASDAQ: AMGN) today announced the launch of the first Amgen Scholars Program in India at the International Institute of Information Technology ... https://www.biopharmawatch.com/news/AMGN/repatha-chmp-positive-opinion-amgen BiopharmaWatch en 2026-07-31T00:00:00.000Z KLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ Společnost Amgen (NASDAQ: AMGN) dnes oznámila, že Výbor pro léčivé přípravky pro humánní použití (CHMP) Evropské agentury pro léčivé přípravky (EMA)... https://www.biopharmawatch.com/news/AMGN/chmp-positive-opinion-repatha-amgn BiopharmaWatch en 2026-07-31T00:00:00.000Z ПОЛОЖИТЕЛЬНАЯ ОЦЕНКА CHMP ПОДДЕРЖИВАЕТ БОЛЕЕ ШИРОКОЕ ПРИМЕНЕНИЕ ПРЕПАРАТА REPATHA® КОМПАНИИ AMGEN ДЛЯ СНИЖЕНИЯ РИСКА ПЕРВОГО ИНФАРКТА ИЛИ ИНСУЛЬТА Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Комитет по лекарственным препаратам для медицинского применения (CHMP) Европейского агентства... https://www.biopharmawatch.com/news/TLX/telix-h1-2026-results-investor-webcast-notification BiopharmaWatch en 2026-07-30T22:37:00.000Z Telix H1 2026 Results: Investor Webcast Notification https://www.biopharmawatch.com/news/REPL/replimune-fda-advisory-committee-rp1-advanced-melanoma BiopharmaWatch en 2026-07-30T22:15:00.000Z Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-participate-canaccord-conference BiopharmaWatch en 2026-07-30T21:57:00.000Z Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/DBVT/dbv-technologies-sale-50-million-ads-atm-program BiopharmaWatch en 2026-07-30T21:40:00.000Z DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-69-per-share BiopharmaWatch en 2026-07-30T20:30:00.000Z STERIS Raises Dividend to $0.69 per share https://www.biopharmawatch.com/news/CLLS/cellectis-second-quarter-financial-results-2026 BiopharmaWatch en 2026-07-30T20:30:00.000Z Cellectis to Report Second Quarter Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-third-quarter-2026 BiopharmaWatch en 2026-07-30T20:15:00.000Z CooperCompanies Announces Release Date for Third Quarter 2026 https://www.biopharmawatch.com/news/ENTA/sars-cov-2-resistance-pathways-edp-235 BiopharmaWatch en 2026-07-30T20:05:16.000Z SARS-CoV-2 Resistance Pathways to EDP-235 https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-q2-2026-results-clinical-milestones BiopharmaWatch en 2026-07-30T20:05:00.000Z Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-canaccord-growth-conference-2023 BiopharmaWatch en 2026-07-30T20:05:00.000Z Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q2-2026-results-conference-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-q2-2026-investor-update-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call https://www.biopharmawatch.com/news/PRTA/prothena-report-q2-2026-results-august-6 BiopharmaWatch en 2026-07-30T20:05:00.000Z Prothena to Report Second Quarter 2026 Financial Results on August 6 https://www.biopharmawatch.com/news/GH/guardant-health-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FLGT/fulgent-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Fulgent Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ILMN/illumina-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q2-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Castle Biosciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/PEN/penumbra-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Penumbra, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CV/capsovision-second-quarter-2026-results-release BiopharmaWatch en 2026-07-30T20:05:00.000Z CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ABVX/abivax-positive-pre-nda-interaction-fda-obefazimod BiopharmaWatch en 2026-07-30T20:05:00.000Z Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T20:05:00.000Z Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 https://www.biopharmawatch.com/news/SYK/stryker-second-quarter-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Stryker reports second quarter 2026 operating results https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability https://www.biopharmawatch.com/news/DXCM/dexcom-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:02:00.000Z Dexcom Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CERS/cerus-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Cerus Corporation Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-30T20:01:00.000Z Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/CDNA/caredx-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z CareDx Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-third-quarter-dividend BiopharmaWatch en 2026-07-30T20:01:00.000Z AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND https://www.biopharmawatch.com/news/GRAL/grail-presentation-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-corporate-update-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-kathleen-kennedy-svp-sales-marketing BiopharmaWatch en 2026-07-30T20:01:00.000Z InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing https://www.biopharmawatch.com/news/ANNX/annexon-secures-credit-facility-200-million BiopharmaWatch en 2026-07-30T20:01:00.000Z Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q2-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/KROS/keros-therapeutics-milestone-payment-takeda BiopharmaWatch en 2026-07-30T20:01:00.000Z Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/XENE/xenon-report-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Xenon to Report Q2 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2026-financial-results-release BiopharmaWatch en 2026-07-30T20:00:00.000Z Mdxhealth to Release Second Quarter 2026 Financial Results on August 13 https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-financial-results-h1-2026 BiopharmaWatch en 2026-07-30T20:00:00.000Z Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-private-placement-nasdaq BiopharmaWatch en 2026-07-30T18:23:00.000Z 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/SRXH/srx-global-acquires-shares-jersey-mikes-ipo BiopharmaWatch en 2026-07-30T18:04:00.000Z SRX Global Acquires Shares in Jersey Mike’s $1 Billion Initial Public Offering https://www.biopharmawatch.com/news/AMGN/repatha-cmuh-favorable-opinion-cardiovascular-risk BiopharmaWatch en 2026-07-30T16:45:00.000Z AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC https://www.biopharmawatch.com/news/ELV/elevance-health-connected-cancer-care-model BiopharmaWatch en 2026-07-30T16:00:00.000Z Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey